CIRM Funded Clinical Trials

Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells


Michael Lewis
Disease Area: 
Pulmonary Hypertension
Investigator:
CIRM Grant:
Award Value:
$7,354,772
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
26
ClinicalTrials.gov ID:
Details: 

Pulmonary arterial hypertension (PAH) is a progressive condition with no cure, survival is poor. Cardiosphere-derived cells (CDCs) decrease wall thickening of lung small blood vessels in preclinical studies. Improvement in lung blood vessels is expected to reduce cardiac right ventricular dysfunction.

Design: 

Phase 1a: dose escalation, safety. Phase 1b: randomized, placebo-controlled safety/efficacy. Single dose, central intravenous infusion.

Goal: 

Primary: Safety. Secondary: Exploratory efficacy measures of right ventricular function.

Status: 

This study is currently recruiting participants.